Pascal Biosciences Inc. (TSXV:PAS)


Pascal Biosciences Inc. is a healthcare company that focuses on developing and researching products, solutions, and innovative therapies for treating serious diseases such as cancer and boosting the immune system. It provides therapy for acute lymphoblastic leukemia and treats cancer patients with cannabinoid-based treatments.

Its cannabinoid portfolio consists of various programs such as PAS-403 that is in a clinical trial for treating glioblastoma. This program was founded in Dr. Nephi Stella’s (a famous cannabis researcher) laboratory.

PAS-393 is an immunity booster cannabinoid that provides treatment for multiple cancers and is used combined with checkpoint inhibitor therapy. This program helps in getting back the immunogenicity of tumor cells.

Checkpoint inhibitors are drugs that are engaged in activating the immune system to destroy tumor cells. The PAS-393 program uses SoRSE Technology and is also expected to treat COVID-19 in the future.

Additionally, the company is working on a B-cell targeted antibody that would treat B-cell lymphomas and lymphoblastic leukemia. The company’s headquarters is in Vancouver, Canada.

Pascal Biosciences Inc. is a publicly listed company on the TSX Venture Exchange Market (TSXV), where its common stocks trade under the ticker of ‘PAS’. In addition to the TSXV, the biopharmaceutical company is also listed on the OTC Market and the Frankfurt Stock Exchange (FSE) under the ticker symbols ‘PSCBF’and ‘6PB-FF’, respectively.

It was established in 2013 and got its technology license from the University of British Columbia. Pascal Biosciences is engaged in developing additional value with the help of various programs that are licensed from different corporations and the company’s in-house discovery research.

It mainly focuses on developing cancer treatment and is committed to developing innovative technologies and uses its expertise and scientific team for developing creative and effective therapeutics.

The company aims to provide treatment to all patients that suffer from diseases such as glioblastoma, and COVID-19. It develops cannabinoid-based treatments and targeted antibodies.

Contact Information

company address 4000 Mason Road, Suite 304 Seattle, WA 98195

company phone604 839-4111

company email[email protected]

company website

Similar Companies

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK